CCL2 and type 1 diabetes mellitus: Correlating with this decline in chemokine secretion, FGF9, which is known to increase expression of pro‐inflammatory chemokines like CCL2 in the central nervous system56 exhibited lower levels in T1D iDCs treated with BL001.